Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,470.00
(
-1.06%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,590.01
(
0.10%
)
News Focus
News Focus
Post# of 257265
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: poorgradstudent post# 68811

Thursday, 05/14/2009 11:44:50 PM

Thursday, May 14, 2009 11:44:50 PM

Post# of 257265

GNVC: One other piece of important data is probably the balance of post-TNFerade treatments between arms. Did more people on TNFerade progress and move to gemzar / tarceva as compared to the SOC?

According to the abstract I just posted, the answer is No.

It's just very suspicious that the clinical benefit arises 8-10 months after drug injection. Post-treatment therapy becomes a big question in such scenarios, imo.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today